Information Provided By: 
Fly News Breaks for June 10, 2019
FGEN
Jun 10, 2019 | 08:53 EDT
Jefferies analyst Michael Yee says his recent meeting with FibroGen management suggested the company's progress is well on track, with the FDA meeting soon. There could be more disclosure with an FDA agreement soon and a new drug application filing on time in Q3, which "should calm the Street," Yee tells investors in a research note. The analyst thinks the post-FDA meeting disclosure, confirmation of filing, and potentially more detailed data from Phase III could cause shares of FibroGen to rebound.
News For FGEN From the Last 2 Days
There are no results for your query FGEN
